Literature DB >> 224983

Low density lipoprotein binding, internalization, and degradation in human adipose cells.

A Angel, M A D'Costa, R Yuen.   

Abstract

Human adipose tissue derives its cholesterol primarily from circulating lipoproteins. To study fat cell-lipoprotein interactions, low density lipoprotein (LDL) uptake and metabolism were examined using isolated human adipocytes. The 125I-labelled LDL (d = 1.025-1.045) was bound and incorporated by human fat cells in a dose-dependent manner with an apparent Km of 6.9 + 0.9 microgram LDL protein/mL and a Vmax of 15-80 microgram LDL protein/mg lipid per 2 h. In time-course studies, LDL uptake was characterized by rapid initial binding followed by a linear accumulation for at least 4 h. The 125I-labelled LDL degradation products (trichloroacetic acid soluble iodopeptides) accumulated in the incubation medium in a progressive manner with time. Azide and F- inhibited LDL internalization and degradation, suggesting that these processes are energy dependent. Binding and cellular internalization of 125I-labelled LDL lacked lipoprotein class specificity in that excess (25-fold) unlabelled very low density lipoprotein (VLDL) (d less than 1.006) and high density lipoprotein (HDL) (d = 1.075-1.21) inhibited binding and internalization of 125I-labelled LDL. On an equivalent protein basis HDL was the most potent. The 125I-labelled LDL binding to an adipocyte plasma membrane preparation was a saturable process and almost completely abolished by a three- to four-fold greater concentration of HDL. The binding, internalization, and degradation of LDL by human adipocytes resembled that reported by other mesenchymal cells and could account for a significant proportion of in vivo LDL catabolism. It is further suggested that adipose tissue is an important site of LDL and HDL interactions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224983     DOI: 10.1139/o79-073

Source DB:  PubMed          Journal:  Can J Biochem        ISSN: 0008-4018


  7 in total

1.  Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism.

Authors:  L H Block; M Knorr; E Vogt; R Locher; W Vetter; P Groscurth; B Y Qiao; D Pometta; R James; M Regenass
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Characterization of high density lipoprotein binding to human adipocyte plasma membranes.

Authors:  B S Fong; P O Rodrigues; A M Salter; B P Yip; J P Despres; A Angel; R E Gregg
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

3.  Characterization of plasma lipoproteins in swine with different propensities for obesity.

Authors:  T D Etherton; P M Kris-Etherton
Journal:  Lipids       Date:  1980-10       Impact factor: 1.880

4.  Abnormal high density lipoproteins in cerebrotendinous xanthomatosis.

Authors:  V Shore; G Salen; F W Cheng; T Forte; S Shefer; G S Tint; F T Lindgren
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

5.  Metabolism of apolipoprotein E-containing human plasma lipoproteins by rat and human cells in culture.

Authors:  S Ranganathan; H Matsuura; M Yamamoto; B A Kottke
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

6.  Influence of obesity on the metabolism of apolipoprotein B in humans.

Authors:  G Egusa; W F Beltz; S M Grundy; B V Howard
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

Review 7.  Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.

Authors:  Thomas Grewal; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.